Navigation Links
IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S.
Date:5/11/2010

EDMONTON, May 11 /PRNewswire/ - IMBiotechnologies Ltd. ("IMBio"), a privately held biotechnology company focused on developing medical device products for use in the area of embolotherapy, today announced that it has received regulatory concurrence from the United States Food and Drug Administration (FDA) to market its lead product, Occlusin(R) 500 Artificial Embolization Device (OCL 500) in the U.S. for the treatment of unresectable/inoperable hypervascularized tumours. IMBio filed the 510(k) submission in December 2009. OCL 500 is the first biodegradable embolization device cleared for marketing by the FDA.

OCL 500 is a patented, first in class embolization agent that represents a paradigm shift in treatment compared to currently marketed embolic agents. OCL 500 is a microspherical agent in development for the treatment of highly vascularised tumours, including hepatocellular carcinoma (HCC; liver cancer), renal cell carcinoma (RCC; kidney cancer) and uterine fibroids. OCL 500 microspheres rapidly form a tight, efficient, site-specific and platelet-rich clot that cuts off the blood supply to tumours. The OCL 500 microspheres then completely biodegrade over time, allowing the treated blood vessels to re-open and restore normal blood flow. This is important because it enables multiple embolization treatments of unresectable hypervascularized tumours, such as those associated with liver and kidney cancer, through the same vascular pathway.

Mike Stewart, CEO of IMBio, stated, "No other embolization agent on the market today offers the advantages that OCL 500 microspheres offer. We believe that OCL 500 has the potential to broadly expand the number of embolization treatments conducted each year, and we are delighted to bring this very exciting product to the U.S. market. We plan to launch OCL 500 with a commercialization partner in the latter half of this year."

About IMBio

IMBio is a privately held Canadian biotechnology company focused on developing medical device products for use in the area of embolotherapy. Lead product, OCL 500 microspheres for the treatment of unresectable/inoperable hypervascularized tumours has received marketing clearance from the FDA in the U.S. Other products in development include rapidly-dissolving, drug-eluting and/or radio-labelled microspheres as well as biodegradable coils and stents for use in aneurysms that are not conducive to treatment with microspheres.

About Embolotherapy

Embolotherapy works by cutting off blood flow to benign and malignant hypervascular tumours. The procedure is performed by injecting agents through a catheter into the blood vessels that feed the target tumour. By selectively blocking blood supply, the deprived tumour is either destroyed or devitalized, resulting in therapeutic benefit. Hypervascular tumours are characterized by having an excessive number of blood vessels. Embolotherapy is a minimally invasive treatment for hypervascular tumours such as liver and kidney cancers as well as uterine fibroids. According to the National Cancer Institute, there are approximately 25,000 Americans with liver and intrahepatic bile duct cancer, and approximately 266,000 with kidney and renal pelvic cancer. Across the U.S., approximately 300,000 hysterectomies and 70,000 myomectomies are performed annually to treat uterine fibroids.

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiary, may ultimately prove to be incorrect. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.


<<
IMBiotechnologies Ltd.             IMBiotechnologies Ltd.
Michael Stewart                    Jean-Paul Laurin
President & CEO                    Vice President, Business Development
(780) 945-6609                     (905) 220-9933
mstewart(at)tbwifi.ca              jp.imbiotechnologies(at)bell.net

www.imbiotechnologies.com
>>


'/>"/>
SOURCE IMBiotechnologies Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
2. InterMune Receives FDA Complete Response Letter on Esbriet(TM) (Pirfenidone) New Drug Application
3. Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee
4. LS9's UltraClean Diesel&#8482; Receives EPA Registration
5. Drug Safety Firm BioSoteria Receives 2009 Best of Business Award
6. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
7. Indiana Collaborative Receives $10.3 Million in Federal Stimulus Funds to Improve Healthcare through Information Technology
8. Advanced Life Sciences Receives FDA Guidance on Approval Pathway for Restanza in Community Acquired Bacterial Pneumonia and Biodefense Indications
9. MedShape Solutions, Inc. Announces Commercialization of SBIR Funded Technology: Receives Purchasing Preference in Federally Funded Hospitals and Health Care Facilities
10. Gems Sensors & Controls Receives ISO-13485:2003 Certification
11. BioMS Medical reports Spectral receives FDA approval to initiate pivotal trial and closes financing for $19.5 million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... ... February 16, 2017 , ... Avomeen & MichBio will be ... will be held at Avomeen Analytical Services (4840 Venture Dr., Ann Arbor, Michigan 48108). ... They provide an opportunity to interact with peers, make new connections and talk bio ...
(Date:2/16/2017)... CALABASAS, Calif. , Feb. 16, 2017 /PRNewswire/ ... on developing groundbreaking therapies to treat severe neurological ... in children treated with AGT-181, the company,s investigational ... syndrome (also known as mucopolysaccharidosis type I, or ... Phase 2 proof-of-concept (POC) study, presented today at ...
(Date:2/16/2017)... 2017 Patient Care services ... telemedicine application, new and leading edge therapies and ... boom worldwide. The healthcare sector as whole continues ... and new therapies for companies such as Reliq ... Biosciences, Inc. (NASDAQ: CLRB ), Cytori ...
(Date:2/16/2017)... ... February 16, 2017 , ... AxioMed announced today the ... Harvard trained surgeon, completed the procedure on Monday, Jan. 30 at Andrews Memorial ... physician suffering from degenerative disc disease with radiculomyelopathy, as a result of degenerative ...
Breaking Biology Technology:
(Date:2/1/2017)... , February 1, 2017 IDTechEx Research, ... on emerging technology, announces the availability of a new report, ... Continue Reading ... ... industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, ...
(Date:1/26/2017)... DENVER , Jan. 26, 2017  Acuity ... Trends for Biometrics and Digital Identity".  Acuity characterizes ... digital identity when increased adoption reflects a new ... "Biometrics and digital identity are ... says Maxine Most , Principal of Acuity ...
(Date:1/23/2017)...  The latest mobile market research from Acuity Market ... The quarterly average price of a biometric smartphone decreased ... 2016.  There are now 120 sub-$150 models on the ... just 28 a year ago at an average price ... Most , Acuity Market Intelligence Principal, "Biometric Smartphones are ...
Breaking Biology News(10 mins):